Limits...
Keratinocyte growth factor-2 intratracheal instillation significantly attenuates ventilator-induced lung injury in rats.

Bi J, Tong L, Zhu X, Yang D, Bai C, Song Y, She J - J. Cell. Mol. Med. (2014)

Bottom Line: Inflammatory cytokines (tumour necrosis factor-α, macrophage inflammatory protein 2), neutrophil and total protein levels in bronchoalveolar lavage fluid and surfactant protein mRNA expression in lung tissue were detected; the number of alveolar type II cells, lung water content and lung morphology were also evaluated.The results indicate that pre-treatment with KGF-2 showed dramatic improvement in lung oedema and inflammation compared with HVZP alone, together with increased surfactant protein mRNA and alveolar type II cells.Our results suggest that KGF-2 might be considered a promising prevention for human VILI or other acute lung injury diseases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Show MeSH

Related in: MedlinePlus

KGF-2 reduces neutrophil infiltration and inflammatory cytokines in the BALF. (A) The number of neutrophil in the bronchoalveolar lavage fluid (BALF). The number of neutrophil in the BALF in HVZP group was significantly higher than those in the control group (P < 0.05). KGF-2 pre-treatment significantly decreased the number of neutrophil in the BALF compared with the HVZP group (P < 0.05). (B) Lung myeloperoxidase (MPO) activity. MPO activity in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MPO activity compared with the HVZP group (P < 0.05). (C) Tumour necrosis factor (TNF)-α in BALF. TNF-α in BALF in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased TNF-α in BALF compared with the HVZP groups (P < 0.05). (D) Macrophage inflammatory protein (MIP)-2 level in BALF was significantly higher in HVZP group than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MIP-2 level in BALF compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508161&req=5

fig02: KGF-2 reduces neutrophil infiltration and inflammatory cytokines in the BALF. (A) The number of neutrophil in the bronchoalveolar lavage fluid (BALF). The number of neutrophil in the BALF in HVZP group was significantly higher than those in the control group (P < 0.05). KGF-2 pre-treatment significantly decreased the number of neutrophil in the BALF compared with the HVZP group (P < 0.05). (B) Lung myeloperoxidase (MPO) activity. MPO activity in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MPO activity compared with the HVZP group (P < 0.05). (C) Tumour necrosis factor (TNF)-α in BALF. TNF-α in BALF in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased TNF-α in BALF compared with the HVZP groups (P < 0.05). (D) Macrophage inflammatory protein (MIP)-2 level in BALF was significantly higher in HVZP group than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MIP-2 level in BALF compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.

Mentions: The number of neutrophil in the BALF and lung MPO activity were significantly increased in rats ventilated with HVZP than other animals (P < 0.05, Fig.2A and B). Meanwhile, KGF-2 pre-treatment significantly decreased neutrophil counts and MPO activity (P < 0.05, Fig.2A and B). Both TNF-α and MIP-2 in the BALF were significantly increased in HVZP group compared with those in the control group (P < 0.05, Fig.2C and D). Keratinocyte growth factor-2 pre-treatment significantly decreased TNF-α and MIP-2 in the BALF compared with those in the HVZP group (P < 0.05, Fig.2C and D).


Keratinocyte growth factor-2 intratracheal instillation significantly attenuates ventilator-induced lung injury in rats.

Bi J, Tong L, Zhu X, Yang D, Bai C, Song Y, She J - J. Cell. Mol. Med. (2014)

KGF-2 reduces neutrophil infiltration and inflammatory cytokines in the BALF. (A) The number of neutrophil in the bronchoalveolar lavage fluid (BALF). The number of neutrophil in the BALF in HVZP group was significantly higher than those in the control group (P < 0.05). KGF-2 pre-treatment significantly decreased the number of neutrophil in the BALF compared with the HVZP group (P < 0.05). (B) Lung myeloperoxidase (MPO) activity. MPO activity in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MPO activity compared with the HVZP group (P < 0.05). (C) Tumour necrosis factor (TNF)-α in BALF. TNF-α in BALF in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased TNF-α in BALF compared with the HVZP groups (P < 0.05). (D) Macrophage inflammatory protein (MIP)-2 level in BALF was significantly higher in HVZP group than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MIP-2 level in BALF compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508161&req=5

fig02: KGF-2 reduces neutrophil infiltration and inflammatory cytokines in the BALF. (A) The number of neutrophil in the bronchoalveolar lavage fluid (BALF). The number of neutrophil in the BALF in HVZP group was significantly higher than those in the control group (P < 0.05). KGF-2 pre-treatment significantly decreased the number of neutrophil in the BALF compared with the HVZP group (P < 0.05). (B) Lung myeloperoxidase (MPO) activity. MPO activity in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MPO activity compared with the HVZP group (P < 0.05). (C) Tumour necrosis factor (TNF)-α in BALF. TNF-α in BALF in HVZP group was significantly higher than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased TNF-α in BALF compared with the HVZP groups (P < 0.05). (D) Macrophage inflammatory protein (MIP)-2 level in BALF was significantly higher in HVZP group than those in control group (P < 0.05). KGF-2 pre-treatment significantly decreased MIP-2 level in BALF compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
Mentions: The number of neutrophil in the BALF and lung MPO activity were significantly increased in rats ventilated with HVZP than other animals (P < 0.05, Fig.2A and B). Meanwhile, KGF-2 pre-treatment significantly decreased neutrophil counts and MPO activity (P < 0.05, Fig.2A and B). Both TNF-α and MIP-2 in the BALF were significantly increased in HVZP group compared with those in the control group (P < 0.05, Fig.2C and D). Keratinocyte growth factor-2 pre-treatment significantly decreased TNF-α and MIP-2 in the BALF compared with those in the HVZP group (P < 0.05, Fig.2C and D).

Bottom Line: Inflammatory cytokines (tumour necrosis factor-α, macrophage inflammatory protein 2), neutrophil and total protein levels in bronchoalveolar lavage fluid and surfactant protein mRNA expression in lung tissue were detected; the number of alveolar type II cells, lung water content and lung morphology were also evaluated.The results indicate that pre-treatment with KGF-2 showed dramatic improvement in lung oedema and inflammation compared with HVZP alone, together with increased surfactant protein mRNA and alveolar type II cells.Our results suggest that KGF-2 might be considered a promising prevention for human VILI or other acute lung injury diseases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Show MeSH
Related in: MedlinePlus